Leukemia Clinical Trials in Houston

Showing 861-880 of 1,435 trials

Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

NCT02982941

This study is a Phase 1, open-label, dose escalation and cohort expansion trial designed to characterize the safety, tolerability, PK, PD, immunogenicity and preliminary antitumor activity of enoblituzumab administered IV on a weekly schedule for up to 96 doses (approximately 2 years) in children and young adults with B7-H3-expressing relapsed or refractory malignant solid tumors.

NeuroblastomaRhabdomyosarcomaOsteosarcoma+3 more

MacroGenics25 participantsStarted Dec 2016

Palo Alto, California, United States • Bethesda, Maryland, United States • Philadelphia, Pennsylvania, United States +3 more locations

COMPLETEDPhase 1< 1 mile

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

NCT02381314

The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Yervoy (ipilimumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC) and other B7-H3 expressing cancers. The study will also evaluate what is the best dose of enoblituzumab to use when given with ipilimumab. Assessments will also be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics) and to evaluate potential anti-tumor activity of enoblituzumab in combination with ipilimumab.

MelanomaNon Small Cell Lung Cancer

MacroGenics24 participantsStarted Mar 2015

Los Angeles, California, United States • New Haven, Connecticut, United States • Miami Beach, Florida, United States +7 more locations

Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

Leukemia Trials in Other Cities

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis

Double Cord Versus Haploidentical (BMT CTN 1101)

Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery

DOSE Trial of Opioid Sparing Effect

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

Safety Study of MGA271 in Refractory Cancer

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

Other Conditions in Houston